Biotoxtech Co., Ltd. (KOSDAQ:086040)

Market Cap	45.51B
Revenue (ttm)	41.34B
Net Income (ttm)	-6.43B
Shares Out	15.72M
EPS (ttm)	-417.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,943
Average Volume	19,654
Open	2,925.00
Previous Close	2,895.00
Day's Range	2,880.00 - 2,960.00
52-Week Range	2,690.00 - 6,800.00
Beta	0.98
RSI	49.02
Earnings Date	May 14, 2025

About Biotoxtech

Biotoxtech Co., Ltd. engages in the safety evaluation of synthetic medicines, biomedicines, cell therapy products, gene therapy products, health functional foods, chemicals, and pesticides in South Korea. It is involved in testing and substance screening, clinical pathology and histopathology work, and consulting and government affairs related to non-clinical trials, as well as new drug development. The company’s safety evaluation research field includes general toxicity test, carcinogenicity studies, local toxicity studies, reproductive and de...

• Industry: Medical Laboratories
• Founded: 2000
• Employees: 198
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086040

Financial Performance

In 2024, Biotoxtech's revenue was 41.34 billion, an increase of 26.69% compared to the previous year's 32.63 billion. Losses were -6.43 billion, 31.8% more than in 2023.